1. Scrip
  2. >>Business

Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Plus Ibrance Generic

 
• By Vibha Ravi

Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar

Patel Sharvil, Zydus Group
Zydus Group Managing Director Sharvil Patel Is Leading The Company's Growth In New Areas • Source: Zydus Lifesciences Ltd

Zydus Lifesciences Limited has been expanding the number of indications for which its novel molecules are being studied as it follows the "pipeline-in-a-drug" model successfully implemented by others like Abbott for Humira (adalimumab) and Sanofi and Regeneron Pharmaceuticals, Inc. for Dupixent (dupilumab).

While the approach has created multibillion-dollar drugs in developed economies like the US, in growing economies like India, where affordability...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

More from Scrip

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.